PREDIX RELEASES FINDINGS FROM PRECLINICAL STUDIES OF PRX-03140

Predix Pharmaceuticals has announced data from several preclinical models suggesting that PRX-03140, a highly selective, proprietary serotonin 4 (5-HT4) receptor agonist, significantly improved cognitive performance and working memory. Study findings also showed that PRX-03140 increased levels of acetylcholine (ACh) in the brain and demonstrated a trend towards reducing levels of specific amyloid proteins. PRX-03140 was further found to increase levels of brain nerve growth factor, a protein that regulates nerve cell development, repair and regeneration, and brain-derived neurotrophic factor, a protein that promotes cell growth and survival.

PRX-03140 is the second of four clinical drug candidates discovered utilizing computer-based G-Protein Coupled Receptors models and optimized with integrated computational-medicinal chemistry.